REC-3964 / Recursion Pharma - LARVOL DELTA

New investigational agents for the treatment of clostridioides difficile infections. (PubMed, Expert Opin Investig Drugs) - "Ibezapolstat, CRS3123, and ridinilazole were identified with unique mechanisms of action and narrow spectrums of activity that result in gut microbiome preservation and reduced recurrent CDI (rCDI) rates...Some have the ability to restore the microbiome (VE303) or preserve intestinal integrity (e.g. REC-3964, LMN-201, AQ)...CDI is a significant burden to the healthcare system and the quality of life for patients who suffer from CDI and rCDI. Further development of these investigational agents to prevent this cycle are of upmost importance."

Journal • Review • Infectious Disease

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=3 | Terminated | Sponsor: Recursion Pharmaceuticals Inc. | N=80 ➔ 3 | Trial completion date: Oct 2026 ➔ May 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2026 ➔ May 2025; Study terminated due to business decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Recursion Pharmaceuticals Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "As part of this prioritization, the Company will discontinue development and/or pursue partnering opportunities for the following clinical programs: REC-3964 (C. difficile): The Company will consider out-licensing opportunities....Evolved treatment options result in low recurrence rates (~5%); thus limiting unmet need. Strategic decision to focus on other areas with greater unmet need."

Discontinued • Infectious Disease

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Recursion Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Recursion Pharmaceuticals Inc.

New P2 trial • Infectious Disease